In the complaint, White River said some of its contract pharmacies have been denied Novo Nordisk’s products through the hospital’s 340B accounts. The drugmaker disagreed with White River but said “the 340B program has been the subject of significant and well-documented abuses.”
“Novo Nordisk continues to support the 340B drug program so that uninsured and vulnerable patients continue to have access to outpatient drugs,” a spokesperson told Becker’s.
The Arkansas Insurance Department Rule 123, which was implemented Sept. 30, states drugmakers cannot “exclude a pharmacy from a network on the basis of a pharmacy’s participation in 340B pricing.”
The alleged restrictions have cost White River about $1 million, according to the complaint.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
